Table 1.
Survey Results Regarding EUA Remdesivir Eligibility Decisions at US Hospitals
| Survey Questions | No. (%) Responses |
|---|---|
| 1. Who was responsible for developing criteria for use and a patient-level allocation plan? (n = 66) | |
| Multidisciplinary team | 65 (98) |
| Authorized individual | 1 (1) |
| 1a. If a multidisciplinary team was created, select all members included. (n = 65) | |
| Clinical pharmacist | 63 (97) |
| Adult infectious diseases physician | 61 (94) |
| Adult intensivist | 45 (69) |
| Adult hospitalist | 32 (49) |
| Ethics committee member | 23 (35) |
| Pediatric infectious diseases physician | 12 (18) |
| Pediatric intensivist | 4 (6) |
| Pediatric hospitalist | 1 (1) |
| Other (administration, other physician and/or pharmacy representation, or epidemiologist) | 20 (31) |
| 2. How are patients eligible for EUA remdesivir identified? (n = 66) | |
| All inpatients with suspected/confirmed COVID-19 are evaluated. | 39 (59) |
| Treating physicians assess and request evaluation for EUA remdesivir. | 33 (50) |
| Only patients with an infectious disease consult are evaluated. | 9 (14) |
| 3. Who makes the daily decision to allocate and/or approve use of EUA remdesivir? (n = 66) | |
| Treating physician and multidisciplinary team | 25 (38) |
| Multidisciplinary team separate from treating physician | 24 (36) |
| Infectious diseases consultant only | 6 (9) |
| Treating physician with or without pharmacist oversight | 6 (9) |
| Antimicrobial stewardship program only | 4 (6) |
| Pharmacist only | 1 (1) |
| 3a. If the treating physician and multidisciplinary team make the daily decision to allocate and/or approve EUA remdesivir, who are the team members? (n = 25) | |
| Infectious diseases consultant | 23 (92) |
| Pharmacist | 21 (84) |
| Antimicrobial stewardship program | 4 (16) |
| Not specified | 2 (8) |
| 3b. If the multidisciplinary team that makes the daily decision to allocate and/or approve EUA remdesivir is separate from the treating physician, who are the team members? (n = 24) | |
| Pharmacist | 9 (37) |
| Infectious diseases consultant | 8 (33) |
| Antimicrobial stewardship program | 6 (25) |
| Intensivist or pulmonary specialist | 2 (8) |
| Hospital command center | 1 (4) |
| State department of health | 1 (4) |
| Hospitalist | 1 (4) |
| Not specified | 11 (46) |
Abbreviations: COVID-19, coronavirus disease 2019; EUA, emergency use authorization.